Fulcrum Therapeutics Inc (FULC)
9.51
+0.03
(+0.32%)
USD |
NASDAQ |
Mar 28, 15:26
Fulcrum Therapeutics Cash from Investing (TTM): -36.69M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -36.69M |
September 30, 2023 | -91.41M |
June 30, 2023 | -112.71M |
March 31, 2023 | -101.19M |
December 31, 2022 | 12.41M |
September 30, 2022 | 39.68M |
June 30, 2022 | -64.68M |
March 31, 2022 | -122.42M |
December 31, 2021 | -129.67M |
September 30, 2021 | -135.17M |
June 30, 2021 | -14.45M |
Date | Value |
---|---|
March 31, 2021 | 11.68M |
December 31, 2020 | -57.14M |
September 30, 2020 | -42.65M |
June 30, 2020 | -56.95M |
March 31, 2020 | -56.95M |
December 31, 2019 | -0.944M |
September 30, 2019 | -4.302M |
June 30, 2019 | -5.014M |
March 31, 2019 | -8.599M |
December 31, 2018 | -8.981M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-135.17M
Minimum
Sep 2021
39.68M
Maximum
Sep 2022
-48.86M
Average
-49.80M
Median
Cash from Investing (TTM) Benchmarks
Pfizer Inc | -32.28B |
NovaBay Pharmaceuticals Inc | -0.017M |
Palatin Technologies Inc | 9.293M |
iBio Inc | 8.285M |
Theriva Biologics Inc | -0.237M |